{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:40:29Z","timestamp":1786117229498,"version":"build-2736575974"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["advancessurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Surgery"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.yasu.2026.03.011","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T19:47:59Z","timestamp":1782503279000},"page":"285-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists"],"prefix":"10.1016","volume":"60","author":[{"given":"Claire B.","family":"Rosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise W.","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yasu.2026.03.011_bib1","author":"Emmerich"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib2","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnz014","article-title":"Review: diabetes, obesity, and cancer-pathophysiology and clinical implications","volume":"41","author":"Lega","year":"2020","journal-title":"Endocr Rev"},{"issue":"14","key":"10.1016\/j.yasu.2026.03.011_bib3","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jacc.2018.08.2141","article-title":"Promoting physical activity and exercise: JACC health promotion series","volume":"72","author":"Fletcher","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"9838","key":"10.1016\/j.yasu.2026.03.011_bib4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(12)60898-8","article-title":"The pandemic of physical inactivity: global action for public health","volume":"380","author":"Kohl","year":"2012","journal-title":"Lancet"},{"issue":"9937","key":"10.1016\/j.yasu.2026.03.011_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(14)60648-6","article-title":"Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA","volume":"384","author":"Bauer","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13088","article-title":"Visceral obesity and incident cancer and cardiovascular disease: an integrative review of the epidemiological evidence","volume":"22","author":"Silveira","year":"2021","journal-title":"Obes Rev"},{"key":"10.1016\/j.yasu.2026.03.011_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clnesp.2022.06.001","article-title":"Sedentary behavior, physical inactivity, abdominal obesity and obesity in adults and older adults: a systematic review and meta-analysis","volume":"50","author":"Silveira","year":"2022","journal-title":"Clin Nutr ESPEN"},{"issue":"6","key":"10.1016\/j.yasu.2026.03.011_bib9","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/ijo.2015.21","article-title":"Obesity-related immune responses and their impact on surgical outcomes","volume":"39","author":"Quante","year":"2015","journal-title":"Int J Obes"},{"issue":"6","key":"10.1016\/j.yasu.2026.03.011_bib10","first-page":"560","article-title":"Perioperative management of obese patient","volume":"24","author":"Bazurro","year":"2018","journal-title":"Curr Opin Crit Care"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0021-9258(18)85474-6","article-title":"Aqueous extracts of pancreas","volume":"58","author":"Kimball","year":"1923","journal-title":"J Biol Chem"},{"key":"10.1016\/j.yasu.2026.03.011_bib12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.yasu.2026.03.011_bib13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1172\/JCI105714","article-title":"Characterization of the responses of circulating glucagon-like immunoreactivity to intraduodenal and intravenous administration of glucose","volume":"47","author":"Unger","year":"1968","journal-title":"J Clin Investig"},{"key":"10.1016\/j.yasu.2026.03.011_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"5910","key":"10.1016\/j.yasu.2026.03.011_bib16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/302716a0","article-title":"Hamster preproglucagon contains the sequence of glucagon and two related peptides [20]","volume":"302","author":"Bell","year":"1983","journal-title":"Nature"},{"issue":"8571","key":"10.1016\/j.yasu.2026.03.011_bib17","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"330","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.yasu.2026.03.011_bib18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/gut.24.2.114","article-title":"Measurement of gut hormonal peptides in biopsies from human stomach and proximal small intestine","volume":"24","author":"Bryant","year":"1983","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1152\/physrev.00031.2014","article-title":"Ghrelin, CCK, GLP-1, and PYY(3-36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB","volume":"97","author":"Steinert","year":"2017","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1124\/pr.55.1.6","article-title":"International union of pharmacology. XXXV. The glucagon receptor family","volume":"55","author":"Mayo","year":"2003","journal-title":"Pharmacol Rev"},{"issue":"11","key":"10.1016\/j.yasu.2026.03.011_bib21","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1210\/en.2011-1070","article-title":"Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance","volume":"152","author":"Vendrell","year":"2011","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.yasu.2026.03.011_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0014-5793(94)01430-9","article-title":"Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences","volume":"358","author":"Wei","year":"1995","journal-title":"FEBS Lett"},{"issue":"7","key":"10.1016\/j.yasu.2026.03.011_bib23","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","article-title":"Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor","volume":"137","author":"Bullock","year":"1996","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.yasu.2026.03.011_bib24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/pr.117.014803","article-title":"Anti-obesity therapy: from rainbow pills to polyagonists","volume":"70","author":"M\u00fcller","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"5","key":"10.1016\/j.yasu.2026.03.011_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2146\/ajhp050459","article-title":"Exenatide","volume":"63","author":"Bray","year":"2006","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"10.1016\/j.yasu.2026.03.011_bib26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4140\/TCP.n.2016.685","article-title":"Liraglutide: a glucagon-like peptide-1 agonist for chronic weight management","volume":"31","author":"Manigault","year":"2016","journal-title":"Consult Pharm"},{"issue":"10","key":"10.1016\/j.yasu.2026.03.011_bib28","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.yasu.2026.03.011_bib29","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1210\/endo.142.5.8128","article-title":"Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic \u03b2-cells by a cyclic adenosine monophosphate\/protein kinase A-dependent mechanism","volume":"142","author":"Wang","year":"2001","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.yasu.2026.03.011_bib30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2337\/diab.38.3.338","article-title":"Glucagonlike peptide I (7-37) actions on endocrine pancreas","volume":"38","author":"Weir","year":"1989","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.yasu.2026.03.011_bib31","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2337\/db09-1414","article-title":"The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action","volume":"59","author":"Hare","year":"2010","journal-title":"Diabetes"},{"issue":"4 48\u20134","key":"10.1016\/j.yasu.2026.03.011_bib32","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1152\/ajpendo.00024.2003","article-title":"Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect","volume":"285","author":"Prigeon","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.yasu.2026.03.011_bib33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.00013.2014","article-title":"Physiology of proglucagon peptides: role ofglucagon and GLP-1 in health and disease","volume":"95","author":"Sandoval","year":"2015","journal-title":"Physiol Rev"},{"issue":"6","key":"10.1016\/j.yasu.2026.03.011_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.yasu.2026.03.011_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrcardio.2011.211","article-title":"The effect of glucagon-like peptide 1 on cardiovascular risk","volume":"9","author":"Sivertsen","year":"2012","journal-title":"Nature Reviews Cardiology"},{"issue":"4","key":"10.1016\/j.yasu.2026.03.011_bib36","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1016\/j.yasu.2026.03.011_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.yasu.2026.03.011_bib38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"110","author":"Sun","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"10.1016\/j.yasu.2026.03.011_bib40","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/dom.12506","article-title":"Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans","volume":"17","author":"van Bloemendaal","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.yasu.2026.03.011_bib41","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.cmet.2011.09.010","article-title":"The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans","volume":"14","author":"De Silva","year":"2011","journal-title":"Cell Metab"},{"issue":"12","key":"10.1016\/j.yasu.2026.03.011_bib42","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2337\/db14-0849","article-title":"GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans","volume":"63","author":"Van Bloemendaal","year":"2014","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.yasu.2026.03.011_bib43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1463-1326.2012.01557.x","article-title":"Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight","volume":"14","author":"Jelsing","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"10.1016\/j.yasu.2026.03.011_bib44","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1523\/JNEUROSCI.6326-11.2012","article-title":"The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors","volume":"32","author":"Dickson","year":"2012","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib45","first-page":"327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (Noninsulin-dependent) diabetic patients","volume":"81","author":"Willms","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.yasu.2026.03.011_bib46","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1210\/jc.2005-2220","article-title":"Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses","volume":"91","author":"Little","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.yasu.2026.03.011_bib47","doi-asserted-by":"crossref","DOI":"10.1152\/ajpregu.00472.2011","article-title":"Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake","volume":"301","author":"Mckay","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"11","key":"10.1016\/j.yasu.2026.03.011_bib48","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.2337\/dc16-1371","article-title":"Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial","volume":"39","author":"Tonneijck","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.yasu.2026.03.011_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.yasu.2026.03.011_bib50","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.yasu.2026.03.011_bib51","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.yasu.2026.03.011_bib52","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/jama.2024.10816","article-title":"Medications for obesity: a review","volume":"332","author":"Gudzune","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.yasu.2026.03.011_bib53","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.yasu.2026.03.011_bib55","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA, J Am Med Assoc"},{"issue":"11","key":"10.1016\/j.yasu.2026.03.011_bib56","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.yasu.2026.03.011_bib57","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib58","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/dc11-0931","article-title":"Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes","volume":"35","author":"Dushay","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib59","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.yasu.2026.03.011_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"The BMJ"},{"issue":"3","key":"10.1016\/j.yasu.2026.03.011_bib61","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/biom15030408","article-title":"Weight reduction with GLP-1 agonists and paths for discontinuation while maintaining weight loss","volume":"15","author":"Reiss","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.yasu.2026.03.011_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.yasu.2026.03.011_bib63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.yasu.2026.03.011_bib64","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib65","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with Glucagon-like peptide-1based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.yasu.2026.03.011_bib66","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1\u2013based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.yasu.2026.03.011_bib67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.23736\/S2724-6507.20.03219-8","article-title":"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"48","author":"Nreu","year":"2023","journal-title":"Minerva Endocrinology"},{"key":"10.1016\/j.yasu.2026.03.011_bib68","article-title":"GLP-1 agonists may raise risk of pulmonary aspiration during surgery, MHRA warns","volume":"388","author":"Mahase","year":"2025","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.yasu.2026.03.011_bib69","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.bja.2023.05.005","article-title":"Clinically significant emesis in a patient taking a long-acting GLP-1 receptor agonist for weight loss","volume":"131","author":"Weber","year":"2023","journal-title":"Br J Anaesth"},{"issue":"8","key":"10.1016\/j.yasu.2026.03.011_bib70","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s12630-023-02440-3","article-title":"Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report","volume":"70","author":"Klein","year":"2023","journal-title":"Can J Anesth"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib71","article-title":"Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss","volume":"12","author":"Avraham","year":"2024","journal-title":"Anaesth Rep"},{"issue":"4","key":"10.1016\/j.yasu.2026.03.011_bib72","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.bja.2024.01.001","article-title":"Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration","volume":"132","author":"van Zuylen","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.yasu.2026.03.011_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinane.2023.111091","article-title":"Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy","volume":"87","author":"Silveira","year":"2023","journal-title":"J Clin Anesth"},{"issue":"12","key":"10.1016\/j.yasu.2026.03.011_bib74","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.soard.2024.08.033","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"20","author":"Kindel","year":"2024","journal-title":"Surg Obes Relat Dis"},{"issue":"4","key":"10.1016\/j.yasu.2026.03.011_bib76","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bja.2023.12.015","article-title":"Perioperative use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus","volume":"132","author":"Dhatariya","year":"2024","journal-title":"Br J Anaesth"},{"issue":"3","key":"10.1016\/j.yasu.2026.03.011_bib77","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/03007995.2025.2458538","article-title":"Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms","volume":"41","author":"Goldenberg","year":"2025","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.yasu.2026.03.011_bib78","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/anae.16541","volume":"80","author":"El-Boghdadly","year":"2025","journal-title":"Anaesthesia"},{"key":"10.1016\/j.yasu.2026.03.011_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinane.2025.111871","article-title":"Perioperative management of patients on GLP-1 receptor agonists: risks, recommendations, and future directions\u2014A narrative review","volume":"104","author":"Li","year":"2025","journal-title":"J Clin Anesth"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib80","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bja.2025.04.001","article-title":"Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: society for perioperative assessment and quality improvement (SPAQI) multidisciplinary consensus statement","volume":"135","author":"Oprea","year":"2025","journal-title":"Br J Anaesth"},{"issue":"1","key":"10.1016\/j.yasu.2026.03.011_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/jmas.jmas_142_23","article-title":"Evaluating the evidence for a liver shrinkage diet for obese patients prior to laparoscopic cholecystectomy: a systematic review and meta-analysis","volume":"20","author":"Hughes","year":"2024","journal-title":"J Minim Access Surg"},{"issue":"8","key":"10.1016\/j.yasu.2026.03.011_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289616","article-title":"The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"18","author":"Liao","year":"2023","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.yasu.2026.03.011_bib83","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.2337\/db24-0861","article-title":"The GLP-1 receptor agonist dulaglutide attenuates hepatic steatosis in obesity via a weight-independent mechanism","volume":"74","author":"Shantaram","year":"2025","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.yasu.2026.03.011_bib84","doi-asserted-by":"crossref","first-page":"336","DOI":"10.2337\/db22-0568","article-title":"The importance of endogenously secreted GLP-1 and GIP for postprandial glucose tolerance and \u03b2-cell function after Roux-en-Y gastric bypass and sleeve gastrectomy surgery","volume":"72","author":"Hinds\u00f8","year":"2023","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.yasu.2026.03.011_bib85","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12323","article-title":"Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery","volume":"9","author":"Wharton","year":"2019","journal-title":"Clin Obes"},{"issue":"10","key":"10.1016\/j.yasu.2026.03.011_bib86","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamasurg.2023.2930","article-title":"Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial","volume":"158","author":"Mok","year":"2023","journal-title":"JAMA Surg"},{"issue":"5","key":"10.1016\/j.yasu.2026.03.011_bib87","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/oby.23736","article-title":"Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence","volume":"31","author":"Murvelashvili","year":"2023","journal-title":"Obesity"},{"issue":"4","key":"10.1016\/j.yasu.2026.03.011_bib88","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11695-023-06484-8","article-title":"Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study","volume":"33","author":"Jensen","year":"2023","journal-title":"Obes Surg"}],"container-title":["Advances in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065341126000114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065341126000114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:26:37Z","timestamp":1786022797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065341126000114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0065341126000114"],"URL":"https:\/\/doi.org\/10.1016\/j.yasu.2026.03.011","relation":{},"ISSN":["0065-3411"],"issn-type":[{"value":"0065-3411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists","name":"articletitle","label":"Article Title"},{"value":"Advances in Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yasu.2026.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}